Karen J. Marcus

Karen J. Marcus

Auto-generated profile, based on publicly available information

Karen J. Marcus

Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Current Problems in Cancer
Verified
Journal Article
Closed access
AOAllison O'Neill
Allison O'Neill
ACAlanna J. Church
Alanna J. Church
APAntonio R. Perez-Atayde
Antonio R. Perez-Atayde
RSRaja Shaikh
Raja Shaikh
KMKaren J. Marcus
Karen J. Marcus
KVKhashayar Vakili
Khashayar Vakili

20 October 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
TCThomas Cash
Thomas Cash
MKMark D. Krailo
Mark D. Krailo
ABAllen B. Buxton
Allen B. Buxton
BPBruce R. Pawel
Bruce R. Pawel
JHJohn Healey
John Healey
RWRichard B. Womer
Richard B. Womer
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Long-term outcomes from Children's Oncology Group study AEWS0031 were assessed to determine whether the survival advantage of interval-compressed chemotherapy (ICC) was maintained over 10 years in patients with localized Ewing sarcoma (ES). AEWS0031 enrolled 568 eligible patients. Patients were randomly assigned to receive vincristine-doxorubicin-cyclophosphamide and ifosfamide-etoposide alternating once every 3 weeks (standard timing chemotherapy [STC]) versus once every 2 weeks (ICC). For this updated report, one patient was excluded because of uncertainty of original diagnosis. The 10-year event-free survival (EFS) was 70% with ICC compared with 61% with STC ( P = .03), and 10-year overall survival (OS) was 76% with ICC compared with 69% with STC ( P = .04). There was no difference in the 10-year cumulative incidence of second malignant neoplasms (SMNs; PC [see Data Supplement, online only] = .5). A test for interaction demonstrated that ICC provided greater risk reduction for patients with tumor volume ≥200 mL than for patients with tumors <200 mL, but no evidence for a significant interaction in other subgroups defined by age, primary site, and histologic response. With longer-term follow-up, ICC for localized ES is associated with superior EFS and OS without an increased risk for SMN compared with STC. ICC is associated with improved outcomes even in adverse-risk patient groups.

26 September 2021 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
THThomas P. Howard
Thomas P. Howard
PBPatrick J. Boyle
Patrick J. Boyle
KMKaren J. Marcus
Karen J. Marcus
DHDaphne A. Haas‐Kogan
Daphne A. Haas‐Kogan
Kevin X. LiuKevin X. Liu
Kevin X. Liu

15 June 2024 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
Kevin X. LiuKevin X. Liu
Kevin X. Liu
SSSherif G. Shaaban
Sherif G. Shaaban
JCJie Jane Chen
Jie Jane Chen
RBRochelle Bagatell
Rochelle Bagatell
BLBenjamin Lerman
Benjamin Lerman
DHDaphne A. Haas-Kogan
Daphne A. Haas-Kogan